Skip to content

Study · In vitro (cells) · 1998

4 results

Autoradiographic discrimination of melanocortin receptors indicates that the MC3 subtype dominates in the medial rat brain.

Lindblom J, Schiöth HB, Larsson A, Wikberg JE, Bergström L

Brain research1 Nov 1998Cited by 57 (Europe PMC)

PMID9813305 (opens in a new tab)DOI10.1016/s0006-8993(98)00918-4 (opens in a new tab)PepBankPUB-09813305
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In COS cells expressing rat MC3 or MC4 receptors, radiolabelled NDP-MSH bound non-selectively to the two receptor subtypes.

    In plain wordsIn cells, NDP-MSH bound the MC3 and MC4 receptors without preferring one of them.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableReceptor selectivity of [125I]NDP-MSH for rat MC3 versus MC4 receptors
    Study

    n: not reported in source

    COS cells expressing rat MC3 or MC4 receptors
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [125I]NDP-MSH was found to be non-selective, whereas gamma1-MSH showed a 40-fold preference for the rat MC3 receptor, and HS014 an over 300-fold preference to the rat MC4 receptor.
    1 context sentence
    Summary · context
    Second, to discriminate between the MC3 and MC4 receptors in rat brain sections, the sections were incubated with [125I]NDP-MSH in the presence of graded concentrations of the MC3 selective ligand, gamma1-MSH, or the MC4 selective ligand, HS014.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 02LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueMechanism

    In rat brain sections, autoradiography with [125I]NDP-MSH as the radioligand showed MC3 receptor dominance in the nucleus accumbens shell, medial preoptic area and ventromedial hypothalamus, and both subtypes in the lateral septum and olfactory tubercle.

    In plain wordsIn rat brain sections, a labelled NDP-MSH tool showed that the MC3 receptor dominates in several brain regions.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableMC3 versus MC4 receptor dominance in rat brain regions
    Study

    ratn: not reported in source

    sagittal rat brain sections
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Our results indicate that in the nucleus accumbens shell, the medial preoptic area, and the ventromedial nucleus of the hypothalamus, there is a clear dominance of the MC3 receptor, whereas in the lateral septum and the olfactory tubercle, there seem to be present both MC3 and MC4 receptors, althoug…
    1 context sentence
    Summary · context
    Second, to discriminate between the MC3 and MC4 receptors in rat brain sections, the sections were incubated with [125I]NDP-MSH in the presence of graded concentrations of the MC3 selective ligand, gamma1-MSH, or the MC4 selective ligand, HS014.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 03LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueMechanism

    In rat brain sections, autoradiography with [125I]NDP-MSH as the radioligand indicated a more abundant expression of the MC4 receptor in the optic layer of the superior colliculus.

    In plain wordsIn rat brain sections, a labelled NDP-MSH tool showed more MC4 receptor in one part of the superior colliculus.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableMC4 receptor expression in the optic layer of the superior colliculus
    Study

    ratn: not reported in source

    sagittal rat brain sections
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    In the optic layer of the superior colliculus, our data indicate a more abundant expression of the MC4 receptor.
    1 context sentence
    Summary · context
    Second, to discriminate between the MC3 and MC4 receptors in rat brain sections, the sections were incubated with [125I]NDP-MSH in the presence of graded concentrations of the MC3 selective ligand, gamma1-MSH, or the MC4 selective ligand, HS014.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 04LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueMechanism

    In rat brain sections, autoradiography with [125I]NDP-MSH as the radioligand suggested an additional MSH-peptide binding site of unknown origin in the ventral tegmental area.

    In plain wordsIn rat brain sections, a labelled NDP-MSH tool pointed to a possible extra binding site of unknown origin in one brain area.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableAdditional MSH-peptide binding site in the ventral tegmental area
    Study

    ratn: not reported in source

    sagittal rat brain sections
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    In the ventral tegmental area, there might be an additional MSH-peptide binding site of unknown origin.
    1 context sentence
    Summary · context
    Second, to discriminate between the MC3 and MC4 receptors in rat brain sections, the sections were incubated with [125I]NDP-MSH in the presence of graded concentrations of the MC3 selective ligand, gamma1-MSH, or the MC4 selective ligand, HS014.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.